Podcasts

New Year, New Hurdles: What's in Store for Biosimilars in 2023

December 18th 2022

On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.

Biosimilars Regulatory Roundup for November 2022—Podcast Edition

December 4th 2022

Podcast

On this episode of Not So Different, we recap some of the big regulatory news to come out of November, including some progress for insulin biosimilars, the European approval of another ranibizumab biosimilar, and the congressional introduction of a US Senate bill that is seeking to nix switching study requirements for interchangeability.

What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

November 27th 2022

Podcast

Chad Pettit, the executive director of marketing and global biosimilars commercial lead at Amgen, discusses the most recent version of Amgen's Biosimilar Trends Report and what the report says about the current biosimilar market and how it could develop in the years to come.

AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?

November 13th 2022

Article

Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.

Biosimilars Policy Roundup for October 2022—Podcast Edition

November 6th 2022

Podcast

On this episode of Not So Different, we recap some of the biosimilar policy news from the around the world during October, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

October 16th 2022

Podcast

In this podcast episode, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discussed the stresses that practices and clinics face when trying to manage biosimilars as well as some policy considerations that administrators should keep in mind as more biosimilars enter the market and are added to formularies.

Biosimilars Oncology Roundup for September 2022—Podcast Edition

October 2nd 2022

Podcast

On this episode of Not So Different, we take a look at some of the big stories regarding oncology biosimilars throughout the month of September, including 2 FDA approvals, and the withdrawal of a European application.

How Health Policy Can Impact Adoption for Adalimumab Biosimilars

September 25th 2022

Article

In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.

What Will Year 1 Look Like for Adalimumab Biosimilars?

September 11th 2022

Podcast

As part of a larger series preparing for the US market entrance of adalimumab biosimilars in 2023, Steven Lucio, PharmD, BCPS, senior principal of pharmacy solutions at Vizient, makes predictions for how the rollout of these biosimilars may play out and offers advice to stakeholders for how to maintain a robust market.

Biosimilars Regulatory Roundup for August 2022—Podcast Edition

September 4th 2022

Podcast

On this episode of Not So Different, we look back at some of the biggest regulatory events to happen in the biosimilar space during August, including 2 European approvals, 2 US approvals, and the advancement of the Inflation Reduction Act of 2022.